Preview complete
The prescreener preview is complete. You may now close the preview.
FES PET/CT in Endocrine Refractory Breast Cancer
Recruiting
18 years - 99 years
Female
Phase
3
85 participants needed
2 Locations
Brief description of study
Patients
with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine
therapy may be eligible for this study. Patients may participate in this
study, if they are at least 18 years of age, most participants will be
receiving care at the clinical practices of the University of Pennsylvania.
Positron
emission tomography (PET/CT) imaging will be used to evaluate estrogen
receptor (ER) activity, in sites of metastatic disease, using the
investigational radiotracer [18F]fluoroestradiol (FES). Imaging
will occur prior to starting new therapy. Some patients may also undergo a
second FES PET/CT scan, at the time of suspected progression of disease to
compare for changes in FES uptake measures.
Patients may undergo primary tumor or metastatic
biopsy, as part of their clinical care. Patients may also be enrolled in a
separate breast cancer biopsy protocol entitled “Metastatic Markers of
Recurrent Tumor Phenotype for Breast Cancer” (METAMORPH). We will ask permission to access tissue collected as part of clinical
biopsy or METAMORPH, if available. If the
patient gives permission, archived tissue may be accessed for the purposes of
this study to perform additional experimental pathology assays.
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Cancer,Breast Cancer,Metastatic Breast Cancer,Recurrent Breast Cancer,ER+ Breast Cancer
-
Age: 18 years - 99 years
-
Gender: Female
Updated on
19 Feb 2024.
Study ID: 821717
Pre-Screener
